SCHEDULE 13D/A: PineBridge Funds Reduce Stake in IBEX Ltd to 9.5% Following Recent Share Sales
Beneficial Ownership Update
PineBridge Global Emerging Markets Partners II, L.P. and related entities have filed an Amendment No. 5 to their Schedule 13D, disclosing a reduction in their beneficial ownership of IBEX Ltd common shares to 9.5% following a series of open market sales.
Summary
- This document is Amendment No. 5 to the Schedule 13D filing by PineBridge Global Emerging Markets Partners II, L.P. (GEM II) and its related entities concerning their ownership in IBEX Ltd.
- The reporting persons, including GEM II, PineBridge GEM II G.P., L.P., John Leone, Pierre Mellinger, and Kevin Clowe, collectively beneficially own 1,255,363 common shares of IBEX Ltd.
- This ownership represents 9.5% of IBEX Ltd's outstanding common shares, a percentage calculated based on 16,764,808 shares outstanding as of October 31, 2024, adjusted for 3,562,341 shares repurchased by IBEX Ltd on November 19, 2024.
- Since the filing of Amendment No. 4 on December 6, 2024, GEM II has sold a total of 159,111 common shares in open market transactions.
- These sales occurred between December 9, 2024, and January 7, 2025, at weighted average prices ranging from $19.9989 to $21.9663 per share.
Sentiment
Score: 4
Explanation: The sentiment is moderately negative because a significant institutional investor has reduced its stake in the company by selling a substantial number of shares. While this could be due to portfolio rebalancing, it generally signals a less bullish outlook from a major holder.
Negatives
- PineBridge Global Emerging Markets Partners II, L.P. and related entities have reduced their beneficial ownership in IBEX Ltd to 9.5%, indicating a decrease in their stake.
- The reporting persons sold a total of 159,111 common shares in the open market between December 9, 2024, and January 7, 2025, which could be interpreted as a reduction in confidence or a portfolio rebalancing by a significant institutional investor.
Future Outlook
NA
Industry Context
This filing reflects a portfolio adjustment by a significant institutional investor in IBEX Ltd. While specific industry trends are not detailed, such a reduction in stake by a large fund can sometimes be interpreted as a re-evaluation of the investment's attractiveness within the broader market or sector, or simply a rebalancing of their global emerging markets portfolio.
Stakeholder Impact
- Shareholders may perceive the reduction in stake by a significant institutional investor as a negative signal, potentially leading to decreased investor confidence or downward pressure on the stock price.
Key Dates
| Date | Description |
|---|---|
| 2022-01-05 | Original Schedule 13D filed with the SEC. |
| 2023-07-13 | Date of amendment to Form 3 filed by GEM II, GEM II GP, Mr. Mellinger and Mr. Clowe, which included a Power of Attorney. |
| 2024-09-17 | Amendment No. 1 to Schedule 13D filed with the SEC. |
| 2024-10-04 | Amendment No. 2 to Schedule 13D filed with the SEC. |
| 2024-10-31 | Date of outstanding common shares calculation (16,764,808 shares) as reported in Issuer's 10-Q. |
| 2024-11-07 | Date Issuer's quarterly report on Form 10-Q was filed with the SEC. |
| 2024-11-19 | Date Issuer repurchased 3,562,341 common shares. |
| 2024-11-20 | Date Issuer's current report on Form 8-K was filed with the SEC, reporting share repurchase. |
| 2024-11-22 | Amendment No. 3 to Schedule 13D filed with the SEC. |
| 2024-12-06 | Amendment No. 4 to Schedule 13D filed with the SEC. |
| 2024-12-09 | GEM II sold 23,735 common shares at $20.0186. |
| 2024-12-10 | GEM II sold 60,958 common shares at $20.1208. |
| 2024-12-13 | GEM II sold 20,000 common shares at $19.9989. |
| 2025-01-03 | Date of event requiring filing of this statement; GEM II sold 37,416 common shares at $21.9663. |
| 2025-01-06 | GEM II sold 15,202 common shares at $21.5610. |
| 2025-01-07 | GEM II sold 1,800 common shares at $21.5067; Date of filing of Amendment No. 5. |
Recommendation
holdKeywords
IBEX Ltd, Schedule 13D, SEC filing, beneficial ownership, share sales, PineBridge Global Emerging Markets Partners II, institutional investor, common shares, equity stake, corporate filing
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.